What A1C Level Is Dangerous? Immediate and Long-Term Risks

An A1C above about 9% sharply raises the risk of kidney disease, nerve damage, vision loss, heart attack, and stroke, and levels above roughly 10% are associated with life-threatening emergencies and, in pregnancy, a high rate of serious adverse outcomes. But danger doesn’t start at a single cutoff. Risk climbs gradually as A1C rises above 7%, and large studies consistently show that the relationship between A1C and death follows a U-shaped curve, meaning levels that are too low can also be harmful. Where your personal “danger zone” begins depends on your age, how long you’ve had diabetes, what medications you take, and whether you’re pregnant.

How A1C Translates to Daily Blood Sugar

A1C reflects the percentage of your hemoglobin that has glucose stuck to it, giving a rough average of your blood sugar over the past two to three months. A landmark study that combined continuous glucose monitors with lab draws established a straightforward conversion: each one-point increase in A1C corresponds to roughly 29 mg/dL of additional average blood glucose. An A1C of 6% works out to an average glucose of about 126 mg/dL, while an A1C of 9% corresponds to roughly 212 mg/dL, and 12% means an average hovering near 298 mg/dL. The conversion held steady across age groups, sexes, and diabetes types.¹ These numbers help put the percentages discussed throughout this article into a context you can compare with a home glucose meter.

Where Risk Starts to Climb

For most adults with diabetes, guidelines generally recommend keeping A1C below 7%. That target isn’t arbitrary. A large UK observational study tracking people with type 2 diabetes found that the hazard of developing kidney disease, nerve damage, and eye disease increased in a graded fashion as A1C rose, with the highest risk category being above roughly 9.6%. At that level, the risk of kidney problems was about 27% higher, neuropathy risk roughly 55% higher, and retinopathy risk about 66% higher compared with better-controlled groups.² These are the so-called microvascular complications, and they affect the small blood vessels feeding organs that depend on fine capillary networks.

Cardiovascular risk follows a similar pattern but starts ticking upward earlier than many people realize. A Canadian population study of more than 600,000 adults without a prior diabetes diagnosis found that men with A1C in the 6.0–6.4% range already had a 38% higher risk of cardiovascular hospitalization compared with men at 5.0–5.4%. At A1C of 6.5% or above, the increased risk jumped to 79% in men and 51% in women.³ The fact that cardiovascular risk was already elevated in men with A1C values considered “normal” underscores that there is no magic line where risk suddenly turns on. It’s a gradient.

Stroke Risk and the Dose-Response Pattern

Stroke deserves its own mention because the data here are especially clear about how risk scales with A1C. A large cohort study of people with type 2 diabetes divided participants into A1C bands and tracked stroke events over time. Compared with the reference group at 6.0–6.9%, those with A1C of 8.0–8.9% had a 23% higher risk of total stroke, those at 9.0–9.9% had a 27% higher risk, and those at 10% or above had a 37% higher risk. For hemorrhagic stroke specifically, the picture was even more dramatic: A1C at or above 10% carried roughly a 51% higher risk.⁴

But the same study revealed something counterintuitive: people with A1C below 6% also had a slightly elevated stroke risk compared with those in the 6.0–6.9% range. This U-shaped curve is one of the most consistent findings across A1C research and shows up in cardiovascular outcomes, stroke, and overall mortality. The body seems to do poorly at both extremes.

The U-Shaped Mortality Curve

Multiple large studies confirm that the relationship between A1C and death is not a straight line going up. Instead, it bends into a U or J shape, with the lowest risk sitting in a moderate range and risk climbing on both sides. Among patients with hypertension, researchers identified the A1C level linked to the lowest all-cause mortality at about 5.3%, and for cardiovascular death specifically at about 5.7%. Above those thresholds, each unit increase in A1C raised the hazard of all-cause death by roughly 14% and cardiovascular death by about 22%.⁵

Among people with both diabetes and cardiovascular disease, a separate study placed the optimal A1C for survival at around 6.9%. Below that threshold, each one-unit drop in A1C was actually associated with a 55% decrease in mortality, reflecting the benefit of getting chronically high blood sugar under control. But above 6.9%, mortality began inching upward again.⁵ The pattern in a Japanese general population without known diabetes was strikingly similar: A1C at or above 6.5% carried a 77% higher risk of cardiovascular events, but A1C below 5.0% also carried a 50% higher risk compared with the 5.0–5.4% reference range.⁶

The ACCORD trial, one of the most influential diabetes studies ever conducted, brought this point home in a troubling way. Participants assigned to an intensive strategy aiming for A1C below 6% saw mortality risk increase steadily as their average A1C rose from 6% to 9%, while those on a standard strategy had their lowest mortality risk between 7% and 8%. Pushing A1C aggressively low with medications appeared to carry a higher risk of death than more moderate control.⁷ The trial was stopped early for the intensive arm because of excess deaths. This result changed how clinicians think about glycemic targets, especially for older adults and people with established heart disease.

Why Very Low A1C Can Be Dangerous

The danger at the low end isn’t really about the A1C number itself. A healthy person whose pancreas naturally keeps blood sugar in a tight range might walk around with an A1C of 5.0% with no trouble at all. The problem arises when medications, particularly insulin and certain oral drugs, push A1C down by causing episodes of hypoglycemia, meaning blood sugar dips below about 70 mg/dL. A study of adults with type 2 diabetes found that those with A1C below 6% had a roughly 25% higher rate of severe hypoglycemia compared with those between 7% and 7.9%, but so did those with very poor control at A1C of 9% or higher.⁸ Both ends of the spectrum carried elevated hypoglycemia risk.

Severe hypoglycemia is not merely unpleasant. It can cause seizures, loss of consciousness, cardiac arrhythmias, and death. In the ACCORD trial, older adults in the intensive treatment arm experienced severe hypoglycemia at annualized rates of about 4.5%, and younger adults in the same arm at about 2.5%.⁹ For the younger subgroup, intensive treatment was associated with a 71% higher risk of cardiovascular death compared with standard treatment, a finding that raised serious alarms about the safety of aggressive glucose lowering in certain populations.

Repeated hypoglycemia leads to another insidious problem: the brain adapts. After enough low-blood-sugar episodes, the normal warning signs, like shaking, sweating, and a racing heart, start to fade. The hormonal alarm system that should kick in to raise blood sugar becomes blunted, with epinephrine release dropping dramatically. Brain imaging studies have found that people who develop this hypoglycemia unawareness show altered glucose uptake in regions of the brain that appear to function as a blood-sugar sensor.¹⁰ Without warning signs, the next severe low can come without any chance to intervene.¹¹

The Danger of Dropping A1C Too Quickly

Even when bringing A1C down is the right goal, doing it too fast can cause harm. A condition known as treatment-induced neuropathy of diabetes occurs when someone who has been running very high blood sugars for a long time suddenly achieves tight control. The conventional threshold is a drop of more than two percentage points of A1C over three months.¹² Symptoms include severe nerve pain, autonomic dysfunction like drops in blood pressure upon standing, gastroparesis, and early worsening of retinopathy and kidney function.

In one study, all subjects who experienced rapid glycemic correction developed severe pain within eight weeks of starting intensive glucose control, and orthostatic hypotension and parasympathetic dysfunction were observed in 69% of them. Retinopathy worsened in every participant.¹³ A larger analysis confirmed that the risk of painful or autonomic neuropathy was significantly higher in people whose A1C dropped compared with those whose A1C didn’t change.¹⁴

This is one reason clinicians sometimes tolerate a high A1C for a while before gradually tightening control. If your A1C is 12% and you want to get to 7%, the safest path is usually a slow descent over many months rather than a crash landing in a few weeks.

Targets Shift with Age

The evidence on intensive control and mortality has directly influenced clinical practice, particularly for older adults. Many health systems have adopted age-dependent A1C targets: below 7% for younger, healthier adults; below 7.5% for adults aged 65 to 75; and below 8% for those over 75. One health system that implemented these relaxed targets found that the likelihood of medication changes following an A1C test dropped by about 30% for older patients, reflecting a deliberate step back from aggressive treatment.¹⁵

The reasoning is straightforward: an 80-year-old with multiple health problems is more likely to be harmed by a severe hypoglycemic episode in the next year than by the long-term microvascular damage that might develop over a decade. For that person, an A1C of 8% might be perfectly appropriate, while the same number in a newly diagnosed 35-year-old would warrant urgent attention.

A1C During Pregnancy

Pregnancy imposes its own set of tighter thresholds. For women with type 1 diabetes, a study of 933 pregnancies found that the risk of serious adverse outcomes (including congenital malformations and perinatal death) increased significantly once the A1C measured around conception exceeded 6.9%. At A1C above 10.4%, the rate of serious adverse outcomes reached 16%, and congenital malformation rates rose sharply. Perinatal mortality was elevated even at A1C levels below 6.9%, making pregnancy another arena where the relationship between A1C and harm is not straightforward.¹⁶ For this reason, women with diabetes planning a pregnancy are generally advised to optimize their A1C before conceiving, ideally getting as close to normal as safely possible.

When A1C Doesn’t Tell the Truth

A1C is treated as the gold standard for glycemic control, but it has blind spots. Because the test measures glucose attached to hemoglobin, anything that affects red blood cell lifespan or hemoglobin structure can skew the result. Iron deficiency anemia, for instance, tends to push A1C readings higher for a given blood sugar level, meaning some people look worse controlled than they actually are. A study comparing anemic and non-anemic groups found that the specificity of A1C for diagnosing diabetes dropped significantly in the anemic group, reaching only 81.1% at the standard 6.5% cutoff.¹⁷ Recent research suggests that elevated iron may also distort A1C, possibly by changing how quickly red blood cells turn over or how readily hemoglobin binds glucose.¹⁸

Racial and ethnic differences add another layer. Studies have documented that for the same average blood glucose, Black individuals tend to have higher A1C values than White individuals, with Asian individuals falling somewhere in between. The reasons are still being worked out, but possible contributors include differences in red cell survival, the balance of glucose between the inside and outside of cells, and genetic factors that affect how readily hemoglobin gets glycated.¹⁹ Newer research using continuous glucose monitors to compute a personalized A1C correction has confirmed that the gap between racial groups is real, though the variation between individuals within the same racial group is at least three times larger than the average gap between groups.²⁰ In other words, knowing someone’s race tells you less about their A1C-to-glucose relationship than simply knowing their individual biology.

For anyone with a condition that affects hemoglobin or red blood cells, including sickle cell trait, thalassemia, chronic kidney disease, recent blood transfusions, and heavy alcohol use, A1C may not be reliable enough to guide treatment decisions on its own. Alternative markers like fructosamine, which reflects glucose control over a shorter two-to-three-week window, can fill the gap.

Beyond A1C and the Role of Continuous Glucose Monitoring

Even in people without conditions that skew A1C, the number has a fundamental limitation: it is an average, and averages hide extremes. Two people with an A1C of 7.5% can have wildly different daily glucose profiles. One might hold steady between 130 and 170 mg/dL all day. The other might swing from 50 to 300 mg/dL, with the peaks and valleys canceling each other out. A1C can’t tell them apart, yet the second person’s wild swings carry their own health risks.²¹

Continuous glucose monitors have introduced metrics that capture what A1C misses. “Time in range,” the percentage of the day spent between 70 and 180 mg/dL, has emerged as a complementary measure that reflects both glycemic variability and hypoglycemia risk.²² A1C tells you where your blood sugar has been on average; time in range tells you how bumpy the ride was getting there. Increasingly, clinicians use both together rather than relying on A1C alone.

The Financial Weight of Uncontrolled A1C

There is also a straightforward economic dimension. An analysis of commercially insured adults with type 2 diabetes in Texas found a statistically significant relationship between A1C level and diabetes-related healthcare costs: higher A1C meant higher spending. The trend held across the board, though the rate of cost increase slowed somewhat above A1C of 8%, possibly because the sickest patients were already accruing heavy costs from established complications. Older age and the presence of additional chronic conditions further amplified the spending.²³ From a purely practical standpoint, every sustained percentage point of A1C above target translates into more doctor visits, more prescriptions, more lab work, and a higher likelihood of hospital stays for complications down the road.